Advanced ovarian carcinoma. Factors infl
โ
Baruch Klein; Geoffrey Falkson; C. F. Smit
๐
Article
๐
1985
๐
John Wiley and Sons
๐
English
โ 402 KB
One hundred ten patients with advanced ovarian carcinoma (Stages IIIA, IIIB, and 1V) were evaluated for survival. They received as first treatment one of the following regimens: melphalan (L-PAM) (41 patients), cyclophosphamide plus methotrexate plus 5-fluorouracil (CMF) (16 patients), cyclophospham